CPC A61K 31/5575 (2013.01) [A61K 31/122 (2013.01); A61K 31/277 (2013.01); A61K 31/353 (2013.01); A61K 31/404 (2013.01); A61K 31/473 (2013.01); A61K 31/475 (2013.01); A61K 31/495 (2013.01); A61K 31/546 (2013.01); A61K 31/609 (2013.01); A61K 33/24 (2013.01); A61K 33/243 (2019.01); A61P 35/00 (2018.01); C12N 2740/15043 (2013.01)] | 7 Claims |
1. A method of treating cancer in a patient in need thereof, the method comprising administering to the patient an inhibitor of thymine DNA glycosylase (TDG) in an amount effective to inhibit TDG in cancer cells, wherein the cancer is melanoma, prostate cancer, pancreatic cancer, breast cancer, colon cancer, lung cancer, or glioblastoma, and wherein the inhibitor of TDG is selected from the group consisting of hexadimethrine bromide, indigotindisulfonate, and protamine chloride.
|